We believe this will be a breakthrough that will reduce the likelihood of becoming infected with coronavirus through the nose, which is where most cases are contracted, said Dr Brian Huber, CEO and founder of Advanced Penetration Technology, which is based out of Indiana and Texas.
This is a big deal. It is the type of protection a lot of people have been hoping for and could be a first line of defence against the COVID virus. It is a powerful and effective layer of prevention, Huber said.
He was speaking after the company released the results of an independent laboratory evaluation of a topical medical formulation that mitigates coronavirus from entering the body through the nasal passages, thereby significantly reducing the likelihood of people becoming infected with the virus.
A recent study by the Massachusetts Institute of Technology (MIT) concluded that people contract COVID-19 and other viruses primarily through the nose. However, virus may still enter a body through the mouth and the eyes.
T3X is an FDA registered, over-the-counter formulation, which means that no prescription is needed. It is easy to use and can be self-administered without the assistance of medical personnel or technicians, the company said.
A London-based research laboratory, Virology Research Services Ltd, evaluated the anti-viral impact of the product, named APT T3X, against Corona Virus (NL63) and Influenza A virus and concluded that it is a highly effective formulation against coronavirus, it said.
The research concludes that APT T3X effectively neutralises viral infectivity within seconds. The anti-viral efficacy supports the topical intranasal use of APT T3X to decrease the viral load of exposure.
Under the conditions tested, APT T3X displays a 99.9% virucidal activity against human coronavirus NL63, the company said.
The testing was performed over two months, in May and June. All definitive anti-viral assays were performed in triplicate, it said.
The product was initially developed eight years ago for resistant-bacterial infections, but its formulation additionally provides powerful anti-fungal and anti-viral therapies. It has no documented side effects. However, patients diagnosed with Lyme disease should be aware of a potential Herx reaction shortly after use, the company said.
A total of 22,864,873 people have contracted coronavirus globally so far, according to the Johns Hopkins University's COVID resource centre.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.